AstraZeneca finds no increased blood clot risk

AstraZeneca said Sunday a review of safety data, showed there was no evidence its vaccine raises the risk of blood clots.

The company’s review covered more than 17 million people vaccinated in the United Kingdom and European Union and comes amid a flurry of suspensions over alleged clotting issues.

Authorities in a number of countries including Ireland, Austria and the Netherlands have suspended the vaccine.

In a statement, the company said, “AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia, in any defined age group, gender, batch or in any particular country.”

The drugmaker added 37 blood-related incidents have been reported so far, which it says is similar across other licensed COVID-19 vaccines.

The company plans to publish the monthly safety report on the European Medicines Agency website within the next week.

AstraZeneca’s vaccine, developed with Oxford University, has been authorized for use in the European Union and other countries but not yet in the United States.

The company is expecting results from U.S. Phase III trials in the coming weeks, when it will then file for emergency authorization.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting